Do patients benefit from omega-3 fatty acids
Source : https://pubmed.ncbi.nlm.nih.gov/38252923/
Omega-3 fatty acids (O3FAs) possess beneficial properties for cardiovascular (CV) health and elevated O3FA levels are associated with lower incident risk for CV disease (CVD.) Yet, treatment of at-risk patients...
EPA-only formulations demonstrate superior efficacy in reducing cardiovascular events compared to mixed O3FA or DHA formulations, likely due to unique mechanisms beyond lipid reduction.
Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients
Source : https://pubmed.ncbi.nlm.nih.gov/38399434/
Dyslipidaemia is a modifiable risk factor commonly associated with diabetes mellitus and prediabetes, with a major impact on the early development of atherosclerotic cardiovascular disease. Various studies have tried to...
Dyslipidaemia in diabetes and prediabetes contributes to early atherosclerosis. This review summarizes current lipid disorder treatments and guideline recommendations for managing dyslipidaemia with various pharmacologic options.
Unveiling Familial Hypercholesterolemia-Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy
Source : https://pubmed.ncbi.nlm.nih.gov/38338916/
Familial hypercholesterolemia (FH) is a genetic disorder primarily transmitted in an autosomal-dominant manner. We distinguish two main forms of FH, which differ in the severity of the disease, namely homozygous...
Familial hypercholesterolemia (FH) is an autosomal-dominant genetic disorder causing high LDL-C levels, leading to premature cardiovascular disease. This review evaluates lipid-lowering therapies and FH's link to early CVD.
C3G and Ig-MPGN-treatment standard
Source : https://pubmed.ncbi.nlm.nih.gov/37604793/
Among the broad spectrum of membranoproliferative glomerulonephritis (MPGN), immunofluorescence distinguishes C3 glomerulopathy (C3G), with predominant C3 deposits, and immunoglobulin-associated MPGN (Ig-MPGN), with combined C3 and Ig. However, there are several...
Accurate diagnosis and targeted therapies for primary C3G and Ig-MPGN may improve outcomes through unsupervised clustering analysis and ongoing complement cascade-targeting trials.
Traditional and novel non-statin lipid-lowering drugs
Source : https://pubmed.ncbi.nlm.nih.gov/37979722/
Non-statin drugs find utility in the management of dyslipidaemia in mixed dyslipidaemia, patients with statin intolerance, and when guidelines directed low-density lipoprotein cholesterol (LDL-C) target cannot be achieved despite maximally...
Non-statin drugs are crucial for managing dyslipidaemia in specific patient groups, especially when LDL-C targets are unachievable with statins alone or in cases of statin intolerance.